Dimicaps

Dimicaps

Dimenhydrinate

motion sickness (marine, automobile, air)),

prevention and treatment of symptoms of vestibular and labyrinth disorders (dizziness, nausea, vomiting), with the exception of symptoms caused by antitumor therapy,

Meniere's disease.

Inside, before eating.

Traffic diseases (sea, road, air): adults and children over 12 years-1-2 tablets 2-3 times a day, children from 3 to 6 years-1/4-1/2 tablets 2-3 times a day, from 7 to 12 years-1/2-1 tablets 2-3 times a day.

Prevention and treatment of symptoms of vestibular and labyrinth disorders (dizziness, nausea, vomiting), with the exception of symptoms caused by antitumor therapy: adults and children over 12 years-1-2 tables 2-3 times a day, children from 3 to 6 years-1/4-1/2 tables 2-3 times a day, from 7 to 12 years-1/2-1 table 2-3 times a day.

Meniere's disease: adults and children over 12 years — 1-2 tablets 2-3 times a day, children from 3 to 12 years-1/2-1 table 2-3 times a day.

The maximum daily dose for adults should not exceed 7 tablets. To prevent kinetosis, take 1-2 tablets 30 minutes before the trip. The duration of use of the drug and the possibility of repeating the course of treatment — in consultation with the doctor.

hypersensitivity to the components of the drug,

epilepsy,

acute exudative and vesicular dermatoses,

pregnancy (first trimester),

the period of breastfeeding.

With caution: convulsive syndrome, angle-closure glaucoma, prostatic hyperplasia, bronchial asthma, cardiovascular diseases, hyperthyroidism, stenosing peptic ulcer, pyloroduodenal obstruction and bladder neck obstruction.

Parameters of the frequency of side effects: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1000, <1/100), rarely (≥1/10000, <1/1000), very rarely (<1/10000), unspecified frequency.

From the blood and lymphatic system: very rarely — hemolytic anemia, agranulocytosis, neutropenia, leukopenia, thrombocytopenia or pancytopenia.

From the immune system: rarely-anaphylactic shock.

Mental disorders: often-mood changes, anxiety, stiffness of movements, infrequently-insomnia.

From the nervous system: often-drowsiness, infrequently-impaired sense of balance, impaired concentration and memory impairment (more often in elderly patients), tremor, lack of coordination, confusion, hallucinations, rarely-headache, sleep disorders, dizziness, orthostatic hypotension, very rarely-paradoxical stimulation of the central nervous system (especially in children).

On the part of the visual organ: rarely-glaucoma, vision problems (pupil dilation, blurred vision or split image).

On the part of the organ of hearing and labyrinth disorders: rarely-ringing in the ears.

From the heart: rarely-rapid heartbeat, tachycardia and hypotension.

From the respiratory system, chest and mediastinal organs: often-nasal congestion.

From the gastrointestinal tract: often — dry mouth, constipation, diarrhea, nausea, abdominal pain.

From the liver and biliary tract: unspecified frequency-impaired liver function (cholestatic jaundice).

From the skin and subcutaneous tissues: rarely-rash, redness.

From the kidneys and urinary tract: often-violation of urination (urinary retention due to anticholinergic action).

General disorders and disorders at the injection site: rarely-edema (less often-Quincke's edema).

If any of the described side effects worsen or the patient has noticed any other side effects not specified in the description, you should inform your doctor.

Symptoms: dry mouth, nose and throat, redness of the face, slow and difficult breathing, confusion, convulsions, hallucinations in children. If these symptoms occur, you should immediately consult a doctor.

Treatment: gastric lavage with a suspension of activated carbon (20-30 g), the appointment of a saline laxative (10-15 g of sodium sulfate), symptomatic therapy, with convulsions in children — phenobarbital (5-6 mg/kg), diazepam.

Blocks histamine H₁- receptors and m-cholinergic receptors of the central nervous system. Depresses the vestibular apparatus of the inner ear, acting primarily on the otoliths, in high doses - on the semicircular channels. It has an antiemetic, anorexigenic, sedative effect, eliminates dizziness.

After oral dimenhydrinate is well absorbed and distributed to organs and tissues. The effect of the drug manifests itself in 15-30 minutes and persists for 3-6 hours. About 78% of dimenhydrinate is associated with blood plasma proteins. Dimengydrinate is metabolized in the liver and is almost completely excreted in the urine within 24 hours. Small amounts are excreted in breast milk. T_1/2 the amount of dimenhydrinate is about 3.5 hours.

• H₁- histamine receptor blocker [H₁- antihistamines]

Increases the effects of atropine, tricyclic antidepressants, catecholamines, barbiturates, alcohol, sedatives and hypnotics, neuroleptics, weakens the effect of corticosteroids, anticoagulants. Reduces the reaction to apomorphine. Reduces the depressive effect of acetylcholine on the heart muscle. The combination with bismuth preparations, scopolamine, painkillers and psychotropic drugs increases the likelihood of visual impairment. It is incompatible with ototoxic antibiotics (streptomycin, neomycin, biomycin, amikacin, kanamycin), because it can mask the symptoms of ototoxicity and contribute to the development of irreversible hearing impairment.